Loading
A phase 1/2 trial of DOC1021 in melanoma, run by Diakonos Oncology Corporation, now recruiting.
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma is a phase 1/2 interventional study registered as NCT07288112 by Diakonos Oncology Corporation, with 35 participants planned, started 2026-04-06 and due to reach its primary completion in 2031-01. Interventions recorded: DOC1021, Tumor resection and pIFN (peginterferon alfa-2a).
Shares DOC1021, Diakonos Oncology and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.